Blocking polyamines to enhance immune responses in head and neck cancer
Official title: Polyamine blockade and anti-tumor immunity in head and neck squamous cell carcinoma
Funded at Washington University · NIH-11112790 · Data updated 2026-11-12
This study is looking at whether stopping the production of certain substances in tumors can help boost the immune system's ability to fight head and neck cancer, which could lead to safer and more effective treatments for patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | May 1, 2025 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $170,208 |
| NIH project number | 1K08DE034837-01 |
| Project ID | NIH-11112790 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with head and neck squamous cell carcinoma who are seeking innovative treatment options.
✕Less likely to help
Patients with other types of cancers or those who do not have head and neck squamous cell carcinoma may not benefit from this research.
What this research studies
This research investigates how blocking polyamine metabolism can improve the immune response against head and neck squamous cell carcinoma (HNSC). The approach focuses on understanding how high levels of polyamines in the tumor microenvironment suppress T cell function and antigen presentation. By inhibiting polyamine synthesis and uptake, the study aims to promote anti-tumor immunity while reducing inflammation. This could lead to the development of less toxic and more effective therapies for patients with HNSC.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted therapies that enhance the immune system's ability to fight head and neck cancer.
How similar studies have gone: Previous research has shown promise in targeting immune responses in cancer treatment, suggesting that this approach could be effective, although it is still an emerging area of study.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Harbison, Richard Alexander — Washington University
- Study coordinator: Harbison, Richard Alexander
Related research
Other NIH-funded projects on the same topics.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Oral cancer recurrence predictor using tumor microbes and gene activity
This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.
-
Data-driven classification of aggressive tissue traits to predict cancer outcomes in HPV-negative head and neck cancer
A clinician-science grant uses data science and AI to identify tissue patterns in HPV-negative head and neck cancer that may predict how long patients stay cancer-free.
-
Targeting PIPKIγi5 to boost immune responses against head and neck cancer
A study to see if blocking a specific enzyme, PIPKIγi5, can make head and neck cancer more visible to the immune system and more responsive to existing immunotherapies.
-
Targeted approaches for lung squamous cell carcinoma with key gene changes
A study at a major university is exploring new targets in lung squamous cell carcinoma to help people with this cancer find better treatments.
-
Baculovirus-based therapy to treat head and neck cancer with a gentle, minimally invasive approach
A new, minimally invasive approach using baculovirus-delivered CRISPR gene editing aims to treat head and neck squamous cell carcinoma while aiming to preserve essential tissues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.